

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification⁶:
C07K 14/56, A61K 38/21, C12N 15/20,
15/62

(11) International Publication Number: **WO 99/20653**

(43) International Publication Date: 29 April 1999 (29.04.99)

(21) International Application Number: PCT US98/21936

(22) International Filing Date: 20 October 1998 (20.10.98)

(30) Priority Data:
08/954,395 20 October 1997 (20.10.97) US(71) Applicants: PEPGEN CORPORATION [US/US]: 1265 Harbor
Bay Parkway, Alameda, CA 94502 (US); UNIVERSITY
OF FLORIDA [US/US]: 186 Grinter Hall, Gainesville, FL
32611 (US).(72) Inventors: JOHNSON, Howard, M.; 4404 N.W. 75th Street,
Gainesville, FL 32611 (US); PONTZER, Carol, H.; 215
Piping Rock Drive, Silver Springs, MD 20905 (US); VIL-
LARETE, Lorelie, H.; 2485 Shoreline Drive, Alameda, CA
94501 (US); CAMPOS, Jackeline; 14 Orinda Circle, Pitts-
burg, CA 94565 (US).(74) Agents: PETITHORY, Joanne, R. et al.; Dehlinger & Asso-
ciates, P.O. Box 60850, Palo Alto, CA 94306-0850 (US).(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO
patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

*With international search report.**Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.*

(54) Title: LOW-TOXICITY HUMAN INTERFERON-ALPHA ANALOG

	10	20	27	
CDLPETHSLDNRRTLMLLAQMSRISPS				- rhIFN- α
CYLSRKLM LDAREN LKLLDRMNRLSPH				- roIFN- τ
<hr/>				
CYLSRKLM LDAREN LKLLDRMNRLSPH				- IFN α -N0
CYLSRTHSLDNRRTLMLLAQMSRISPS				- IFN α -N1
CYLSRKLM LDNRRTLMLLAQMSRISPS				- IFN α -N2
CYLSRKLM LDAREN LMLLAQMSRISPS				- IFN α -N3
CYLSRKLM LDAREN LKLLDRMSRISPS				- IFN α -N4
CDLPEKLM LDAREN LKLLDRMNRLSPH				- IFN α -N5
CDLPETHSLDAREN LKLLDRMNRLSPH				- IFN α -N6
CDLPETHSLDNRRTLMLLD RMNRLSPH				- IFN α -N7

(57) Abstract

The present invention describes a method of reducing the cytotoxicity of interferon- α by making defined amino acid substitutions in the N-terminal portion of the polypeptide sequence. Also described are human interferon- α analogs with low cytotoxicity, and therapeutic applications of the low-toxicity interferon- α analogs.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NI	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

LOW-TOXICITY HUMAN INTERFERON-ALPHA ANALOG

Field of the Invention

- 5 The present invention relates to a method of reducing the toxicity of human interferon-alpha, to low-toxicity human interferon-alpha analogs, and to the therapeutic uses of these analogs.

References

- 10 Ausubel, F.M., *et al.*, in CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, Inc., Media, PA (1988).
 Benoit, P., *et al.*, *J. Immunol.* 150(3):707 (1993).
 Bonnem, E.M., *et al.*, *J. Bio. Response Modifiers* 3:580 (1984).
 Davis, G.L., *et al.*, *N. England J. Med.* 321:1501 (1989).
15 DeMaeyer, E., *et al.*, INTERFERONS AND OTHER REGULATORY CYTOKINES, John Wiley and Sons, New York (1988).
 Dianzani, F., *J. Interferon Res., Special Issue*, 5/92:109 (1992).
 Dusheiko, G.M., *et al.*, *J. Hematology* 3(Supl. 2):S199 (1986).
 Eaton, M.A.W., *et al.*, U.S. Patent No. 4,719,180, issued January 12, 1988.
20 Finter, N.B., *et al.*, *Drugs* 42(5):749 (1991).
 Francis, M.L., *et al.*, *AIDS Res. and Human Retroviruses* 8(2):199 (1992).
 Kashima, H., *et al.*, *Laryngoscope* 98:334 (1988).
 Maniatis, T., *et al.*, in MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory (1982).
25 Martin, E.W., In: DISPENSING OF MEDICATION: A PRACTICAL MANUAL ON THE FORMULATION AND DISPENSING OF PHARMACEUTICAL PRODUCTS (Hoover, J.E., Ed.), 8th edition, Mack Publishing Co., Easton, PA., (1976).
 Oldham, R.K., *Hospital Practice* 20:71 (1985).
 Pearson, W.R. and Lipman, D.J., *PNAS* 85:2444-2448 (1988).
30 Pearson, W.R., *Methods in Enzymology* 183:63-98 (1990).
 Pontzer, C.H., *et al.*, *Cancer Res.* 51:5304 (1991).
 Quesada, J.R., *et al.*, *N. England J. Med.* 310:15 (1984).
 Yoshio, T., *et al.*, U.S. Patent No. 4,849,350, issued July 18, 1989.
35 Zoon, K.C., *et al.*, *Methods Enzymol.* 119:312-315 (1986).

Background of the Invention

The interferons (IFNs) have been classified into two distinct groups: type I interferons, including IFN α , IFN β , and IFN ω (also known as IFN α II); and type II interferons, represented by IFN γ (reviewed by DeMaeyer, *et al.*, 1988). In humans, it is estimated that there are at least 17 IFN α non-allelic genes, at least 2 IFN β non-allelic genes, and a single IFN γ gene.

IFN α 's have been shown to inhibit various types of cellular proliferation. IFN α 's are especially useful against hematologic malignancies such as hairy-cell leukemia (Quesada, *et al.*, 1984). Further, these proteins have also shown activity against multiple myeloma, chronic lymphocytic leukemia, low-grade lymphoma, Kaposi's sarcoma, chronic myelogenous leukemia, renal-cell carcinoma, urinary bladder tumors and ovarian cancers (Bonnem, *et al.*, 1984; Oldham, 1985). The role of interferons and interferon receptors in the pathogenesis of certain autoimmune and inflammatory diseases has also been investigated (Benoit, *et al.*, 1993).

IFN α 's are also useful against various types of viral infections (Finter, *et al.*, 1991). Alpha interferons have shown activity against human papillomavirus infection, Hepatitis B, and Hepatitis C infections (Finter, *et al.*, 1991; Kashima, *et al.*, 1988; Dusheiko, *et al.*, 1986; Davis, *et al.*, 1989).

Significantly, however, the usefulness of IFN α 's has been limited by their toxicity: use of interferons in the treatment of cancer and viral disease results in serious side effects, such as fever, chills, anorexia, weight loss, and fatigue (Pontzer, *et al.*, 1991; Oldham, 1985). These side effects often require (i) the interferon dosage to be reduced to levels that limit the effectiveness of treatment, or (ii) the removal of the patient from treatment. Such toxicity has reduced the usefulness of these potent antiviral and antiproliferative proteins in the treatment of debilitating human and animal diseases.

Summary of the Invention

In one aspect, the invention includes methods for reducing the toxicity of human IFN α (HuIFN α). The method comprises substituting one or more of the amino acids at positions 19, 20, 22, 24, and 27 of mature HuIFN α with an amino acid effective to substantially reduce the specific toxicity of the polypeptide when exposed to human mononuclear cells in culture. The majority of the amino acid residues 1-27 in mature HuIFN α remains unchanged.

In one embodiment, the method includes substituting nonconserved amino acids for one or more of the amino acids at positions 19, 20, 22, and 27. In various embodiments, the substituting may include, but is not limited to: substituting a class III amino acid, in particular Asp, for the amino acid at position 19; substituting a class IV amino acid, in particular Arg, for

the amino acid at position 20, substituting a class III amino acid, in particular Asn, for the amino acid at position 22; and substituting a class IV amino acid, in particular His, for the amino acid at position 27. In another embodiment, the substituting may include substituting a class V amino acid, in particular Leu, for the amino acid at position 24.

- 5 In another embodiment, the method comprises substituting the sequence of mature HuIFN α between residues 19-27, with a 9-mer defined by SEQ ID NO:2. In particular, the sequence of mature HuIFN α between residues 19-27 is SEQ ID NO:1. The 9-mer SEQ ID NO:2 corresponds to residues 19-27 of mature ovine interferon-tau (OvIFN τ) and contains residues non-identical to mature HuIFN α at positions 19, 20, 22, 24, and 27. In another
- 10 embodiment, the method comprises substituting the sequence of HuIFN α between residues 11-27 with a 17-mer defined by SEQ ID NO:4. In particular, the sequence of mature HuIFN α between residues 11-27 is SEQ ID NO:3. The 17-mer SEQ ID NO:4 corresponds to residues 11-27 of mature OvIFN τ , and contains residues non-identical to HuIFN α at positions 11, 13, 14, 16, 19, 20, 22, 24, and 27. In another embodiment, the method comprises substituting the sequence of
- 15 HuIFN α between residues 6-27 with a 22-mer defined by SEQ ID NO:6. In particular, the sequence of mature HuIFN α between residues 6-27 is SEQ ID NO:5. The 22-mer SEQ ID NO:6 corresponds to residues 6-27 of mature OvIFN τ , and contains residues non-identical to HuIFN α at positions 6, 7, 8, 11, 13, 14, 16, 19, 20, 22, 24, and 27.

- In a related aspect, the invention includes a method for reducing the toxicity of HuIFN α .
- 20 The method includes substituting, for one or more of the amino acids at positions 19, 20, 22, 24, and 27 of mature HuIFN α , an amino acid effective to substantially reduce the specific toxicity of the polypeptide in mononuclear cells in culture, where the mature HuIFN α sequence between residues 28-166 is substantially unchanged. In one embodiment, said substituting is accomplished by substituting the sequence of HuIFN α between residues 1-27 with the 27-mer
- 25 defined by SEQ ID NO:8. In particular, the sequence of mature HuIFN α between residues 1-27 is SEQ ID NO:7. The 27-mer SEQ ID NO:8 corresponds to residues 1-27 of mature OvIFN τ , and contains residues non-identical to mature HuIFN α at positions 2, 4, 5, 6, 7, 8, 11, 13, 14, 16, 19, 20, 22, 24, and 27.

- In another aspect, the invention includes a low-toxicity human IFN α analog for use in
- 30 human therapy. This analog comprises a mature HuIFN α protein having, at one or more of the amino acid positions 19, 20, 22, 24, and 27, a substituted amino acid, and the majority of the amino acid residues 1-27 in the analog are native HuIFN α residues. The analog is characterized as having a substantially reduced specific toxicity relative to native human IFN α , as evidenced by an increased viability of mononuclear cells in culture.

In one embodiment, the analog contains a nonconserved amino acid substitution at one or more of the positions 19, 20, 22, and 27. In various embodiments, the substituted amino acid may include, but is not limited to, a class III amino acid, in particular Asp, for the amino acid at position 19; a class IV amino acid, in particular Arg, for the amino acid at position 20; a class III amino acid, in particular Asn, for the amino acid at position 22; and a class IV amino acid, in particular His, for the amino acid at position 27. In another embodiment, the substituted amino acid may include a class V amino acid, in particular Leu, for the amino acid at position 24.

In another embodiment, the analog comprises mature human IFN α substituted between residues 19-27 with the 9-mer of SEQ ID NO:2. In another embodiment, the analog comprises mature human IFN α substituted between residues 11-27 with the 17-mer of SEQ ID NO:4. In another embodiment, the analog comprises mature human IFN α substituted between residues 6-27 with the 22-mer of SEQ ID NO:6.

In a related aspect, the invention includes a low-toxicity human IFN α analog for use in human therapy, comprising a mature human IFN α protein having, at one or more of the amino acid positions 19, 20, 22, 24, and 27, a substituted amino acid, with the mature human IFN α sequence between residues 28-166 being substantially unchanged. The analog is characterized by a substantially reduced specific toxicity relative to native mature human IFN α as evidenced by an increased viability of mononuclear cells in culture. In one embodiment, the analog comprises mature human IFN α substituted between residues 1-27 with the 27-mer of SEQ ID NO:8.

The invention further includes a method of inhibiting tumor cell growth. In the method, the tumor cells are contacted with a low-toxicity IFN α analog of the type described above at a concentration effective to inhibit growth of the tumor cells. The low-toxicity IFN α analog may be a part of any acceptable pharmacological formulation. Tumor cells whose growth may be inhibited by a low-toxicity IFN α analog include, but are not limited to, carcinoma cells, hematopoietic cancer cells, leukemia cells, lymphoma cells, and melanoma cells. In one embodiment, the tumor cells are steroid-sensitive tumor cells, for example, mammary tumor cells.

In yet another aspect of the present invention, a low-toxicity IFN α analog of the type described above is used in a method of inhibiting viral replication. In this method, cells infected with a virus are contacted with the low-toxicity IFN α compound at a concentration effective to inhibit viral replication within said cells. The low-toxicity IFN α may be a part of any acceptable pharmacological formulation. The replication of both RNA and DNA viruses may be inhibited by low-toxicity human IFN α . Exemplary RNA viruses include feline leukemia virus, ovine progressive pneumonia virus, ovine lentivirus, equine infectious anemia virus, bovine

immunodeficiency virus, visna-maedi virus, caprine arthritis encephalitis virus, human immunodeficiency virus (HIV) or hepatitis c virus (HCV). An exemplary DNA virus is hepatitis B virus (HBV).

In still another aspect, the present invention includes a method of treating an autoimmune disease in a subject in need of such treatment. In one embodiment, the autoimmune disease is multiple sclerosis. The method includes administering, to the subject, a pharmaceutically effective amount of a low-toxicity human IFN α analog of the type described above.

In another aspect, the present invention includes a method of treating chronic inflammation in a subject in need of such treatment. In one embodiment, the chronic inflammation arises from ulcerative colitis. The method includes administering, to the subject, a pharmaceutically effective amount of a low-toxicity human IFN α analog of the type described above.

In yet another aspect, the invention includes a method of treating any disease condition which is responsive to intravenously-administered IFN α , by orally administering a low-toxicity human IFN α analog of the type described above. Orally-administered analog is preferably ingested by the subject.

These and other objects and features of the invention will be more fully appreciated when the following detailed description of the invention is read in conjunction with the accompanying drawings.

Brief Description of the Figures

Figure 1 shows the alignment of the first 27 N-terminal amino acids of a mature HuIFN α , mature OvIFN τ , and eight mature HuIFN α analogs designated IFN α -N0 through IFN α -N7.

Brief Description of the Sequences

SEQ ID NO:1 is the amino acid sequence of a mature human IFN α (mHuIFN α) between residues 19-27.

SEQ ID NO:2 is the amino acid sequence of mature ovine interferon-tau (mOvIFN τ) between residues 19-27.

SEQ ID NO:3 is the amino acid sequence of a mHuIFN α between residues 11-27.

SEQ ID NO:4 is the amino acid sequence of mOvIFN τ between residues 11-27.

SEQ ID NO:5 is the amino acid sequence of a mHuIFN α between residues 6-27.

SEQ ID NO:6 is the amino acid sequence of mOvIFN τ between residues 6-27.

SEQ ID NO:7 is the amino acid sequence of a mHuIFN α between residues 1-27.

SEQ ID NO: 8 is the amino acid sequence of mOvIFN τ between residues 1-27.

SEQ ID NO: 9 is the amino acid sequence of a mature HuIFN α (IFN α -d; GenBank Accession No. J00210; PID g386796).

SEQ ID NO: 10 is the amino acid sequence of mature IFN α analog IFN α -N0.

5 SEQ ID NO: 11 is the amino acid sequence of mature IFN α analog IFN α -N1.

SEQ ID NO: 12 is the amino acid sequence of mature IFN α analog IFN α -N2.

SEQ ID NO: 13 is the amino acid sequence of mature IFN α analog IFN α -N3.

SEQ ID NO: 14 is the amino acid sequence of mature IFN α analog IFN α -N4.

SEQ ID NO: 15 is the amino acid sequence of mature IFN α analog IFN α -N5.

10 SEQ ID NO: 16 is the amino acid sequence of mature IFN α analog IFN α -N6.

SEQ ID NO: 17 is the amino acid sequence of mature IFN α analog IFN α -N7.

SEQ ID NO: 18 is the amino acid sequence of mature OvIFN τ (oTP-1; GenBank Accession No. Y00287; PID g1358).

SEQ ID NO: 19 is the nucleotide sequence of a synthetic gene encoding IFN α -N0.

15 SEQ ID NO: 20 is the nucleotide sequence for Linker1.

SEQ ID NO: 21 is the nucleotide sequence for Linker2.

SEQ ID NO: 22 is the nucleotide sequence for Fragment N1, forward strand.

SEQ ID NO: 23 is the nucleotide sequence for Fragment N1, reverse strand.

SEQ ID NO: 24 is the nucleotide sequence for Fragment N2, forward strand.

20 SEQ ID NO: 25 is the nucleotide sequence for Fragment N2, reverse strand.

SEQ ID NO: 26 is the nucleotide sequence for Fragment N3, forward strand.

SEQ ID NO: 27 is the nucleotide sequence for Fragment N3, reverse strand.

SEQ ID NO: 28 is the nucleotide sequence for Fragment N4, forward strand.

SEQ ID NO: 29 is the nucleotide sequence for Fragment N4, reverse strand.

25 SEQ ID NO: 30 is the nucleotide sequence for Fragment N5, forward strand.

SEQ ID NO: 31 is the nucleotide sequence for Fragment N5, reverse strand.

SEQ ID NO: 32 is the nucleotide sequence for Fragment N6, forward strand.

SEQ ID NO: 33 is the nucleotide sequence for Fragment N6, reverse strand.

SEQ ID NO: 34 is the nucleotide sequence for Fragment N7, forward strand.

30 SEQ ID NO: 35 is the nucleotide sequence for Fragment N7, reverse strand.

Detailed Description of the Invention

I. Definitions

Interferon-alpha (IFN α) refers to any one of a family of interferon proteins having
35 greater than 70%, or preferably greater than about 80%, or more preferably greater than about

90% amino acid identity to the mature IFN α protein sequence presented as SEQ ID NO:9.

Amino acid identity can be determined using, for example, the LALIGN program with default parameters. This program is found in the FASTA version 1.7 suite of sequence comparison programs (Pearson and Lipman 1988; Pearson, 1990; program available from William R.

- 5 Pearson, Department of Biological Chemistry, Box 440, Jordan Hall, Charlottesville, VA). Typically, IFN α has at least one characteristic from the following group of characteristics: (a) anti-viral properties, (b) anti-cellular proliferation properties, and (c) inducible by nucleic acids or by viruses. Preferred IFN α 's are from human.

- 10 *Interferon-tau* (IFN τ) refers to any one of a family of interferon proteins having greater than 70%, or preferably greater than about 80%, or more preferably greater than about 90% amino acid identity to the mature IFN τ sequence presented as SEQ ID NO:18. Typically, IFN τ has at least one characteristic from the following group of characteristics: (a) expressed during embryonic/fetal stages by trophectoderm/placenta, (b) anti-luteolytic properties, (c) anti-viral properties, and (d) anti-cellular proliferation properties. Preferred IFN τ 's are ovine and bovine
- 15 IFN τ .

"*Mature protein*" refers to the IFN protein after removal of the leader sequence. The mature IFN protein sequence begins with residue Cys 24 of the complete IFN amino acid sequence, which corresponds to Cys 1 of the mature protein sequence.

- A polynucleotide sequence or fragment is "*derived from*" another polynucleotide
- 20 sequence or fragment when it contains the same sequence of nucleotides as are present in the sequence or fragment from which it is derived. For example, a bacterial plasmid contains an insert "derived from" a selected human gene if the sequence of the polynucleotides in the insert is the same as the sequence of the polynucleotides in the selected human gene.

- Similarly, a polypeptide sequence or fragment is "*derived from*" another polypeptide
- 25 sequence or fragment when it contains the same sequence of amino acids as are present in the sequence or fragment from which it is derived.

- Percent (%) identity, with respect to two amino acid sequences, refers to the % of residues that are identical in the two sequences when the sequences are optimally aligned and no penalty is assigned to "gaps". In other words, if a gap needs to be inserted into a first sequence
- 30 to optimally align it with a second sequence, the % identity is calculated using only the residues that are paired with a corresponding amino acid residue (*i.e.*, the calculation does not consider residues in the second sequences that are in the "gap" of the first sequence). Optimal alignment is defined as the alignment giving the highest % identity score. Such alignments can be preformed using the "GENEWORKS" program. Alternatively, alignments may be performed
- 35 using the local alignment program LALIGN with a ktup of 1, default parameters and the default

PAM.

A "conservative substitution" refers to the substitution of an amino acid in one class by an amino acid in the same class, where a class is defined by common physiochemical amino acid sidechain properties and high substitution frequencies in homologous proteins found in nature (as determined by a standard Dayhoff frequency exchange matrix). Six general classes of amino acid sidechains, categorized as described above, include: Class I (Cys); Class II (Ser, Thr, Pro, Ala, Gly); Class III (Asn, Asp, Gln, Glu); Class IV (His, Arg, Lys); Class V (Ile, Leu, Val, Met); and Class VI (Phe, Tyr, Trp). For example, substitution of an Asp for another class III residue such as Asn, Gln, or Glu, is a conservative substitution.

A "non-conservative substitution" refers to the substitution of an amino acid in one class with an amino acid from another class; for example, substitution of an Ala, a class II residue, with a class III residue such as Asp, Asn, Glu, or Gln.

Treating a disease refers to administering a therapeutic substance effective to reduce the symptoms of the disease and/or lessen the severity of the disease.

II. Low-toxicity Human IFN α Analogs

The present invention is based on the discovery that the cytotoxicity of HuIFN α can be significantly reduced by introducing amino acid substitutions at one or more of amino acid positions 19, 20, 22, 24, and 27 in mature HuIFN α .

Figure 1 shows the first 27 N-terminal amino acid residues of a mature HuIFN α (SEQ ID NO:9) and mature OvIFN τ (SEQ ID NO:18) where the non-identical residues are shown in bold. HuIFN α analogs containing subsets of the OvIFN τ substitutions were prepared as described in Example 1. Positions 1-27 of each HuIFN α analog are shown in Figure 1 with the substitutions shown in bold. Amino acids 28-166 of each analog remain HuIFN α residues (e.g., residues 28-166 of SEQ ID NO:9).

The HuIFN α analogs, designated IFN α -N0 through IFN α -N7 (SEQ ID NO:10 through SEQ ID NO:17), were assayed for cytotoxicity as described in Examples 2 and 3. Hepatocytes incubated with HuIFN α showed significant decreases in viability (Table 1, Example 2). In contrast, cells incubated with the IFN α analog IFN α -N0 showed essentially no loss of viability, as reported in the parent application.

Analog IFN α -N1 through IFN α -N7 were assayed for cytotoxicity as described in Example 3. Peripheral blood mononuclear cells (PBMCs) incubated with varying amounts of OvIFN τ or the analog IFN α -N0 showed essentially no loss of viability after seven days of incubation. PBMCs incubated with the analogs -N1 or -N3 showed significant decreases in viability, with levels similar to that observed for HuIFN α . Substitutions in analogs -N1 and -N3,

at positions 2, 4, 5, 6, 7, 8, 11, 13, and 14, are therefore relatively ineffective in reducing the cytotoxicity of HuIFN α . Cells incubated with IFN α -N4 retained a level of viability between that of cells incubated with HuIFN α and with OvIFN τ . The additional substitutions at positions 16, 19, and 20 are therefore partially effective in reducing the toxicity of HuIFN α .

5 PBMCs incubated with IFN α analogs IFN α -N5, IFN α -N6, and IFN α -N7 showed essentially no loss of viability after seven days of incubation (Table 2). These 3 analogs retain the low cytotoxicity of OvIFN τ and further define the positions responsible for reduced cytotoxicity of HuIFN α . Most strikingly, the analog IFN α -N7 contains only five substitutions, at positions 19, 20, 22, 24, and 27. The other analogs which exhibit low cytotoxicity, -N0, -N5,
10 and -N6, contain substitutions in these positions and in additional positions (Figure 1). The analog IFN α -4, which shows an intermediate level of cytotoxicity in this test, lacks the substitutions at positions 22, 24, and 27. The data demonstrate that residue positions 19, 20, 22, 24, and 27, play a significant role in the cytotoxicity of these proteins, in accordance with the invention.

15 More specifically, the present invention contemplates a HuIFN α analog containing one or more amino acid substitutions at positions 19, 20, 22, 24 and 27, with the majority of the remaining amino acids native HuIFN α residues. The analog possesses reduced toxicity as measured by the cytotoxicity assays described herein, along with therapeutic properties associated with native human IFN α .

20 Preferred substitutions include one or more of the following: amino acid 19 of mature HuIFN α may be substituted with Asp 19 of mature OvIFN τ , or with a same-class residue Asn, Gln, or Glu; amino acid 20 of mature HuIFN α may be substituted with Arg 20 of mature OvIFN τ or with a same-class residue His or Lys; amino acid 22 of mature HuIFN α may be substituted with Asn 22 of mature OvIFN τ or with a same-class residue Asp, Gln, or Glu; amino
25 acid 24 of mature HuIFN α may be substituted with Leu 24 of mature OvIFN τ or with a same-class residue Val or Met; and amino acid 27 of mature HuIFN α may be substituted with His 27 of OvIFN τ or with a same-class residue Arg or Lys. Such substitutions are effective to reduce the toxicity of HuIFN α but not significantly alter desirable HuIFN α therapeutic properties.

Other exemplary sequences which encompass the altered positions of some low-toxicity
30 HuIFN α analogs include the sequences presented herein as SEQ ID NO:2, SEQ ID NO:4, and SEQ ID NO:6. Most preferred embodiments are HuIFN α analogs substituted in the 19-27 region in positions which are non-identical in OvIFN τ . For example, constructs where amino acids 19-27 of mature human IFN α (SEQ ID NO:1) are substituted for amino acids 19-27 of mature OvIFN τ (SEQ ID NO:2), result in the alteration of positions 19, 20, 22, 24, and 27 in

mature human IFN α , while the remaining mature human IFN α sequence remains unchanged. This example corresponds to the analog IFN α -N7 (SEQ ID NO:17).

It will be appreciated that although the low-toxicity human IFN α analogs described are "mature" proteins, that is, they begin with residue Cys 24 of the complete interferon sequence (which corresponds to Cys 1 of the mature protein), the invention also includes IFN α analogs which contain the leader sequence, *i.e.*, that begin with the initiation methionine. The leader sequence in such human IFN α analogs may be derived from human IFN α , ovine IFN τ , or another type I interferon.

As pointed out above, a considerable advantage contemplated for HuIFN α analogs of the present invention is reduced toxicity of the analogs relative to native human IFN α . The HuIFN α analogs may have the same biological activity as the native human IFN α .

III. Recombinant and Synthetic Manipulations

The construction of a synthetic gene encoding HuIFN α analog IFN α -N0 is described in Example 1A. Briefly, amino acid sequence of mature HuIFN α containing all 15 OvIFN τ substitutions within the first 27 N-terminal positions (SEQ ID NO:10) was back translated with codon usage optimized for *Pichia pastoris*. The nucleotide sequence was edited to include five restriction sites spaced throughout the length of the construct. The synthetic gene sequence was divided into four nucleotide fragments. The individual fragments, each approximately 150 base pairs in length, were constructed by sequential ligations of oligonucleotides. The fragments were sequentially cloned into a bacterial vector to yield the gene encoding IFN α -N0 (SEQ ID NO:19). The synthetic gene was then cloned into the pPICZ- α vector for expression in *Pichia pastoris*. The synthetic genes encoding analogs IFN α -N1 through IFN α -N7 were also constructed by sequential ligations of oligonucleotides as described in Example 1A.

Expression of the synthetic genes in *Pichia* (Example 1B) allowed overproduction of recombinant HuIFN α analogs. The recombinant HuIFN α analogs exhibited antiviral activity (Example 1C) similar to the antiviral activity of recombinant OvIFN τ expressed using the same *Pichia pastoris* system.

IV. Utility

A. Antiviral Properties

Type I interferons exhibit potent antiviral properties. The reduced toxicity of IFN τ with respect to IFN α appears to be attributable to non-conserved amino acids present within the first 27 N-terminal residues of the mature protein. Substitution of these amino acid residues for the

corresponding residues in the N-terminal portion of IFN α appears to counter reduced cytotoxicity to the resulting HuIFN α analogs while the antiviral activity of Type I interferons is retained. Thus, formulations comprising low-toxicity HuIFN α analogs of the present invention may be used to inhibit viral replication.

5 The low-toxicity HuIFN α analogs of the present invention can be employed in methods for affecting the immune relationship between fetus and mother, for example, in preventing transmission of maternal viruses (*e.g.*, HIV) to the developing fetus. The human interferon analogs are particularly useful for treatment of humans, since potential antigenic responses are less likely using a homologous protein.

10

B. Anticellular Proliferation Properties

Type I interferons exhibit potent anticellular proliferation activity. Low-toxicity human IFN α analogs such as described herein can also be used to inhibit cellular growth without the negative side effects associated with other interferons which are currently known. Formulations
15 comprising the low-toxicity IFN α analogs of the present invention can be used to inhibit, prevent, or slow tumor growth.

C. Immune System Disorders

Diseases which may be treated using methods of the present invention include
20 autoimmune, inflammatory, proliferative and hyperproliferative diseases, as well as cutaneous manifestations of immunologically mediated diseases. In particular, methods of the present invention are advantageous for treating conditions relating to immune system hypersensitivity. There are four types of immune system hypersensitivity. Type I, or immediate/anaphylactic hypersensitivity, is due to mast cell degranulation in response to an allergen (*e.g.*, pollen), and
25 includes asthma, allergic rhinitis (hay fever), urticaria (hives), anaphylactic shock, and other illnesses of an allergic nature. Type II, or autoimmune hypersensitivity, is due to antibodies that are directed against perceived "antigens" on the body's own cells. Type III hypersensitivity is due to the formation of antigen/antibody immune complexes which lodge in various tissues and activate further immune responses, and is responsible for conditions such as serum sickness,
30 allergic alveolitis, and the large swellings that sometimes form after booster vaccinations. Type IV hypersensitivity is due to the release of lymphokines from sensitized T-cells, which results in an inflammatory reaction. Examples include contact dermatitis, the rash of measles, and "allergic" reactions to certain drugs.

The mechanisms by which certain conditions may result in hypersensitivity in some
35 individuals are generally not well understood, but may involve both genetic and extrinsic factors.

For example, bacteria, viruses or drugs may play a role in triggering an autoimmune response in an individual who already has a genetic predisposition to the autoimmune disorder. It has been suggested that the incidence of some types of hypersensitivity may be correlated with others.

For example, it has been proposed that individuals with certain common allergies are more susceptible to autoimmune disorders.

Autoimmune disorders may be loosely grouped into those primarily restricted to specific organs or tissues and those that affect the entire body. Examples of organ-specific disorders (with the organ affected) include multiple sclerosis (myelin coating on nerve processes), type I diabetes mellitus (pancreas), Hashimoto's thyroiditis (thyroid gland), pernicious anemia (stomach), Addison's disease (adrenal glands), myasthenia gravis (acetylcholine receptors at neuromuscular junction), rheumatoid arthritis (joint lining), uveitis (eye), psoriasis (skin), Guillain-Barré Syndrome (nerve cells) and Grave's disease (thyroid). Systemic autoimmune diseases include systemic lupus erythematosus and dermatomyositis.

Other examples of hypersensitivity disorders include asthma, eczema, atopic dermatitis, contact dermatitis, other eczematous dermatitides, seborrheic dermatitis, rhinitis, Lichen planus, Pemphigus, bullous Pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythemas, cutaneous eosinophilias, Alopecia areata, atherosclerosis, primary biliary cirrhosis and nephrotic syndrome. Related diseases include intestinal inflammations, such as Crohn's disease, proctitis, eosinophilia gastroenteritis, mastocytosis, inflammatory bowel disease, Crohn's disease and ulcerative colitis, as well as food-related allergies.

Autoimmune diseases particularly amenable for treatment using the methods of the present invention include multiple sclerosis, type I (insulin dependent) diabetes mellitus, lupus erythematosus, amyotrophic lateral sclerosis, Crohn's disease, rheumatoid arthritis, stomatitis, asthma, uveitis, allergies and psoriasis.

Medicaments containing low-toxicity HuIFN α analogs of the present invention may be used to therapeutically treat and thereby alleviate symptoms of autoimmune disorders such as those discussed above.

D. Pharmaceutical Compositions

Low-toxicity human IFN α analogs of the present invention can be formulated according to known methods for preparing pharmaceutically useful compositions. Formulations comprising interferons or interferon-like compounds have been previously described (for example, Martin, 1976). In general, the compositions of the subject invention will be formulated such that an effective amount of the interferon analog is combined with a suitable carrier in order to facilitate effective administration of the composition.

The compositions used in these therapies may also be in a variety of forms. These include, for example, solid, semi-solid, and liquid dosage forms, such as tablets, pills, powders, liquid solutions or suspensions, liposomes, suppositories, injectable, and infusible solutions. The preferred form depends on the intended mode of administration and therapeutic application. The compositions also preferably include conventional pharmaceutically acceptable carriers and adjuvants which are known to those of skill in the art. Preferably, the compositions of the invention are in the form of a unit dose and will usually be administered to the patient one or more times a day.

Low-toxicity human IFN α analogs or related polypeptides may be administered to a patient in any pharmaceutically acceptable dosage form, including oral intake, inhalation, intranasal spray, intraperitoneal, intravenous, intramuscular, intralesional, or subcutaneous injection. Specifically, compositions and methods used for other interferon compounds can be used for the delivery of these analogs.

One primary advantage of the IFN α analogs of the subject invention, however, is their extremely low cytotoxicity. Because of this low toxicity, it is possible to administer the interferon analogs in concentrations which are greater than those which can generally be utilized for other interferon (*e.g.*, native human IFN α) compounds. Thus, it is contemplated that low-toxicity HuIFN α analogs of the present invention can be administered at rates from about 5×10^4 to 20×10^6 units/day to about 500×10^6 units/day or more. In a preferred embodiment, the dosage is about 20×10^6 units/day. High doses are preferred for systemic administration. It should, of course, be understood that the compositions and methods of this invention may be used in combination with other therapies.

Once improvement of a patient's condition has occurred, a maintenance dose is administered if necessary. Subsequently, the dosage or the frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained. When the symptoms have been alleviated to the desired level, treatment should cease. Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.

The IFN α analogs of the subject invention can be administered through standard procedures to treat a variety of cancers and viral diseases including those for which other interferons have previously shown activity. See, for example, Finter, *et al.*, 1991; Dianzani, 1992; Francis, *et al.*, 1992, and U.S. Patent Nos. 4,885,166 and 4,975,276. However, as discussed above, the IFN α analogs of the subject invention have unique features and advantages, including their ability to treat these conditions without toxicity.

E. Treatment of Skin Disorders

Disorders of the skin can be treated intralesionally using low-toxicity interferon analogs of the present invention, wherein formulation and dose will depend on the method of administration and on the size and severity of the lesion to be treated. Preferred methods include intradermal and subcutaneous injection. Multiple injections into large lesions may be possible, and several lesions on the skin of a single patient may be treated at one time. The schedule for administration can be determined by a person skilled in the art. Formulations designed for sustained release can reduce the frequency of administration.

F. Systemic Treatment

Systemic treatment is essentially equivalent for all applications. Multiple intravenous, subcutaneous and/or intramuscular doses are possible, and in the case of implantable methods for treatment, formulations designed for sustained release are particularly useful. Patients may also be treated using implantable subcutaneous portals, reservoirs, or pumps.

G. Regional Treatment

Regional treatment with the low-toxicity IFN α analogs of the present invention is useful for treatment of cancers in specific organs. Treatment can be accomplished by intraarterial infusion. A catheter can be surgically or angiographically implanted to direct treatment to the affected organ. A subcutaneous portal, connected to the catheter, can be used for chronic treatment, or an implantable, refillable pump may also be employed.

The following examples illustrate, but in no way are intended to limit the present invention.

MATERIALS AND METHODS

Restriction endonucleases, T4 DNA ligase, T4 polynucleotide kinase, *Taq* DNA polymerase, and calf intestinal phosphatase were purchased from New England Biolabs (Beverly, MA) or Promega Biotech (Madison, WI); these reagents were used according to the manufacturer's instructions. For sequencing reactions, a "SEQUENASE DNA II" sequencing kit was used (United States Biochemical Corporation, Cleveland OH). Immunoblotting and other reagents were from Sigma Chemical Co. (St. Louis, MO) or Fisher Scientific (Needham, MA). Nitrocellulose filters are obtained from Schleicher and Schuell (Keene, NH).

Synthetic oligonucleotide linkers and primers were prepared using commercially available automated oligonucleotide synthesizers (e.g., an ABI model 380B-02 DNA synthesizer (Applied Biosystems, Foster City, CA)). Alternatively, custom designed synthetic oligonucleotides may be purchased, for example, from Synthetic Genetics (San Diego, CA). CDNA

synthesis kit and random priming labeling kits were obtained from Boehringer-Mannheim Biochemical (BMB, Indianapolis, IN).

Oligonucleotide sequences encoding polypeptides can be either synthesized directly by standard methods of oligonucleotide synthesis, or, in the case of large coding sequences,

5 synthesized by a series of cloning steps involving a tandem array of multiple oligonucleotide fragments corresponding to the coding sequence (Yoshio, *et al.*, 1989; Eaton, *et al.*, 1988).

Oligonucleotide coding sequences can be expressed by standard recombinant procedures (Maniatis, *et al.*, 1982; Ausubel *et al.*, 1988). Alternatively, peptides can be synthesized directly by standard *in vitro* techniques (Applied Biosystems, Foster City CA).

10 Recombinant Human IFN α A was obtained from Biosource International (Camarillo, CA). Unless otherwise indicated, protein concentration was determined with the bicinchoninic acid assay kit (Pierce, Rockford IL) according to the manufacturer's instructions.

All tissue culture media, sera and IFNs used in this study were negative for endotoxin, as determined by assay with Limulus amoebocyte lysate (Associates of Cape Cod, Woods Hole, MA)

15 at a sensitivity level of 0.07 ng/ml.

EXAMPLE 1

Cloning and Expression of HuIFN α Analogs

A. Construction of Synthetic Genes Encoding HuIFN α Analogs

20 The amino acid sequence of HuIFN α containing all 15 OvIFN τ substitutions within the first 27 N-terminal positions (SEQ ID NO:10) was back translated with codon usage optimized for *Pichia pastoris*. The nucleotide sequence was edited to include five restriction sites spaced throughout the length of the construct. The synthetic gene sequence was divided into four nucleotide fragments. The individual fragments, each approximately 150 base pairs in length,

25 were constructed by sequential ligations of oligonucleotides. The fragments were sequentially cloned into the G2 bacterial vector to yield the gene encoding IFN α -N0 (SEQ ID NO:19). The synthetic gene was then cut out of the bacterial vector and ligated into the *XhoI/NotI* sites of the pPICZ- α vector (Invitrogen, San Diego CA) for expression in *Pichia pastoris*.

The synthetic genes encoding analogs IFN α -N1 through IFN α -N7 were also constructed

30 by sequential ligations of oligonucleotides. The pPICZ- α /IFN α -N0 construct described above was digested with *XbaI* and *BsrEII* and annealed oligonucleotides Linker1 (SEQ ID NO:20) and Linker2 (SEQ ID NO:21) were ligated into these sites to produce an intermediate vector construct. This step removed the nucleotide sequence corresponding to the N-terminal section of IFN α -N0, to be replaced by the nucleotide fragments listed below. The intermediate vector

35 construct was digested with *XhoI* and *EcoRI*. The following nucleotide fragments, prepared by

sequential ligation of oligonucleotides, were then ligated into the *XhoI/EcoRI* sites of the intermediate construct to produce analogs IFN α -N1 through IFN α -N7 in the pPICZ- α vector.

IFN α -N1 Fragment N1 forward SEQ ID NO:22
 Fragment N1 reverse SEQ ID NO:23

IFN α -N2 Fragment N2 forward SEQ ID NO:24
 Fragment N2 reverse SEQ ID NO:25

IFN α -N3 Fragment N3 forward SEQ ID NO:26
 Fragment N3 reverse SEQ ID NO:27

IFN α -N4 Fragment N4 forward SEQ ID NO:28
 Fragment N4 reverse SEQ ID NO:29

IFN α -N5 Fragment N5 forward SEQ ID NO:30
 Fragment N5 reverse SEQ ID NO:31

IFN α -N6 Fragment N6 forward SEQ ID NO:32
 Fragment N6 reverse SEQ ID NO:33

IFN α -N7 Fragment N7 forward SEQ ID NO:34
 Fragment N7 reverse SEQ ID NO:35

B Expression of HuIFN α Analogs in *Pichia*

For expression of the recombinant interferon analogs, the coding sequence of each gene was inserted into the pPICZ- α expression vector (Invitrogen, San Diego, CA) using the *XhoI* and *NorI* restriction endonuclease sites on the vector. The pPICZ- α expression vector provides a variety of elements to facilitate expression and purification of the recombinant interferons. For example, the vector includes an expression cassette containing the methanol-regulated alcohol oxidase (AOX) promoter. In methanol grown yeast cells, approximately 5% of the polyA+ RNA is from the AOX1 gene. In addition, the vector also contains the secretion signal sequence from the *Saccharomyces cerevisiae* α factor prepro peptide which directs the secretion of the protein into the culture medium. The vector also provides selection of recombinant bacteria and yeast cells using the Zeocin antibiotic coded for by the *Sh ble* gene (*Streptoalloteichus hindustanus ble* gene).

The recombinant plasmids encoding HuIFN α analogs were electroporated into the X-33 wild-type *Pichia pastoris* strain for large-scale growth. Recombinant yeast colonies were grown and induced according to the protocols provided by Invitrogen. Supernatants were collected and filtered using a 0.8/0.2 mm pore size acrodisc filter (Gelman Sciences, Ann Arbor, MI) and buffer exchanged with phosphate buffered saline (PBS) using Centriplus-10 concentrators (Amicon, Inc., Beverly, MA). The recombinant

HuIFN α analogs obtained by this method exhibited antiviral activity similar to the antiviral activity of recombinant OvIFN τ expressed using the same *Pichia pastoris* system.

C. Quantitative Antiviral Assay

5 A colorimetric assay was used to quantitate the antiviral activity of the interferon proteins. Madin Darby bovine kidney (MDBK) cells were grown to confluency in 96-well flat bottom plates using Eagle's MEM supplemented with 10% fetal bovine serum (FBS) and antibiotics. Medium was removed and the cells were washed once with sterile PBS. Samples were added in triplicate using serial 10-fold and 2-fold dilutions at 100 μ l/well using Eagle's
10 MEM supplemented with 2% FBS and antibiotics as dilution medium. Interferon samples were added and the cells were incubated for 18 hours at 37°C. Recombinant HuIFN- α A (Biosource Intl.) was used as the standard interferon control. 100 μ l of vesicular stomatitis virus (VSV) was added to the test wells and incubated for an additional 48 hours at 37°C. 100 μ l of medium was removed from each well and replaced with 100 μ l of 0.2% neutral red solution (Gibco-BRL) and
15 incubated for 1 hour at 37°C. All medium was removed and cells were gently washed twice with PBS before addition of 100 μ l of acid alcohol (50% ethanol, 1% acetic acid). The A₅₅₀ of solubilized dye was read with a Bio-Kinetics Reader (Bio-Tek Instruments, Winooski VT). Percent protection was calculated using the following formula:
Percent Protection = 100 \times

$$\frac{\text{AVG (A}_{550} \text{ Test Well)} - \text{AVG (A}_{550} \text{ Virus Control Well)}}{\text{AVG (A}_{550} \text{ Untreated Cell Control Wells)}}$$

20 1 antiviral unit (U) is defined as 50% protection.

EXAMPLE 2

In Vitro Toxicity of IFN α Analogs in Hepatocytes

25 The *in vitro* toxicity of HuIFN α and IFN α analog IFN α -N0 (SEQ ID NO:10; Figure 1) were compared using normal human hepatocytes. Hepatocytes were received as a confluent layer of cells in matrigel-coated 96-well plates from Clonetics Corporation (San Diego, CA). The following day, the medium in the wells was replaced with 100 μ l of a Modified Williams E Medium (Clonetics Corp.) supplemented with 0.1 μ M insulin, 0.1 μ M dexamethasone, 50 μ g/ml
30 gentamicin, and 50 ng/ml amphotericin B. The cells were subsequently treated with 2000 U/ml to 128,000 U/ml of HuIFN α or IFN α -N0. After 4, 6, or 7 days of incubation, 10 μ l of the tetrazolium salt WST-1 (4-3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolol-1-3-benzene disulfonate) (Boehringer Mannheim, Indianapolis IN) was added to each well. WST-1 is cleaved

to formazan by the succinate-tetrazolium reductase system which is present in the mitochondrial respiratory chain and is active only in viable cells. The percentage of viable cells was measured by absorbance at 450 nm and expressed as the percentage of non-interferon treated cells.

The results are shown in Table 1. Values are presented as percent metabolic activity of
5 viable cells in which 100% is equal to the viability of cells treated with medium alone.

Table 1

PERCENT METABOLIC ACTIVITY OF PRIMARY NORMAL HUMAN
HEPATOCYTES AFTER 4, 6, OR 7 DAYS
10 INCUBATION WITH IFN SAMPLES

Days of IFN Treatment	Sample	(UNITS/ML)						
		1.28×10^5	6.4×10^4	3.2×10^4	1.6×10^4	8×10^3	4×10^3	2×10^3
4	rHuIFN- α	70.9	74.4	92.1	72.0	71.3	77.5	91.4
4	IFN α -N0	114.6	130.9	142.4	122.3	112.0	93.5	111.3
6	rHuIFN- α	58.1	68.2	96.3	112.4	76.5	73.6	ND
6	IFN α -N0	118.3	96.2	114.6	129.9	138.6	110.7	ND
7	rHuIFN- α	35.0	47.1	71.4	66.0	82.0	83.0	ND
7	IFN α -N0	94.4	132.0	139.0	97.4	111.7	155.4	ND

ND = not done.

Hepatocytes incubated with HuIFN α showed significant decreases in viability. In
15 contrast, cells incubated with the IFN α analog IFN α -N0 showed essentially no loss of viability in comparison to nontreated cells.

EXAMPLE 3

In Vitro Toxicity of IFN α Analogs in Mononuclear Cells

The *in vitro* toxicity of HuIFN α , OvIFN τ , and human IFN α analogs IFN α -N0 through IFN α -N7 (SEQ ID NO:10 through SEQ ID NO:17; Figure 1) were compared using peripheral blood mononuclear cells (PBMC). The buffy coat fraction of whole blood was diluted 1:4 with PBS and overlaid onto Nycoprep 1.077 (Nycomed Pharma, Oslo, Norway). After
25 centrifugation at $600 \times g$ for 20 minutes at 20°C, the PBMC which band at the interface were removed using a pipette. The cells were washed once with PBS and plated at a concentration of 2×10^5 cells/well in a 96-well plate. The following day the cells were treated with 2000 U/ml to

128,000 U/ml of IFN α , IFN τ , or the IFN α analogs. After seven days of incubation, the tetrazolium salt WST-1 (Boehringer Mannheim), was added to each well. The percentage of viable cells was measured by absorbance at 450 nm and expressed as the percentage of non-interferon treated cells.

- 5 The results are shown in Table 2. Values are presented as percent metabolic activity of viable cells in which 100% is equal to the viability of cells treated with medium alone.

Table 2

PERCENT METABOLIC ACTIVITY OF HUMAN PERIPHERAL
BLOOD MONONUCLEAR CELLS (PBMC) AFTER 7 DAYS
INCUBATION WITH IFN SAMPLES

Sample	UNITS/ML						
	1.28×10^5	6.4×10^3	3.2×10^4	1.6×10^4	8×10^3	4×10^3	2×10^3
rHuIFN- α	64.4	65.0	63.8	74.1	71.6	73.6	92.5
rOvIFN- τ	97.4	105.7	122.5	117.5	90.2	100.9	89.7
IFN α -N0	ND	124.6	138.9	101.7	103.5	103.0	105.7
IFN α -N1	60.0	56.1	60.4	69.3	65.6	ND	ND
IFN α -N3	53.8	64.1	59.0	73.5	63.7	66.6	71.7
IFN α -N4	82.5	80.9	80.5	76.1	89.8	71.1	73.4
IFN α -N5	139.1	118.0	99.2	110.2	82.2	96.8	120.0
IFN α -N6	ND	103.4	116.5	91.4	106.9	96.0	125.3
IFN α -N7	97.5	150.6	96.8	121.5	159.4	111.5	140.3

ND = Not done.

- 15 PBMCs incubated with HuIFN α showed a significant decrease in viability. In contrast, cells incubated with OvIFN τ or with the human IFN α analogs IFN α -N0, IFN α -N5, IFN α -N6, and IFN α -N7 showed essentially no loss of viability after seven days of incubation. Decreases in viability similar to those observed for HuIFN α were observed in cells incubated with IFN α analogs IFN α -N1 and IFN α -N3. Cells incubated with IFN α analog IFN α -N4 showed a small
20 increase in viability over cells incubated with HuIFN α .

While the invention has been described with reference to specific methods and embodiments, it will be appreciated that various modifications and changes may be made without departing from the invention.

IT IS CLAIMED:

1. A method for reducing the toxicity of human IFN α , said method comprising substituting, for one or more of the amino acids at positions 19, 20, 22, 24, and 27 of a
5 mature human IFN α sequence, an amino acid effective to substantially reduce the specific toxicity of the IFN α in mononuclear cells in culture, where the majority of the amino acids at positions 1-27 are native human IFN α amino acids.
2. The method of claim 1, wherein said substituting includes substituting nonconserved
10 amino acids for one or more of the amino acids at positions 19, 20, 22, and 27 of said mature human IFN α sequence.
3. The method of claim 1, wherein said substituting includes one or more of:
15 (a) substituting a class III amino acid for the amino acid at position 19,
(b) substituting a class IV amino acid for the amino acid at position 20,
(c) substituting a class III amino acid for the amino acid at position 22,
(d) substituting a class V amino acid for the amino acid at position 24, and
(e) substituting a class IV amino acid for the amino acid at position 27.
- 20 4. The method of claim 1, wherein said substituting includes one or more of:
(a) substituting Asp for the amino acid at position 19,
(b) substituting Arg for the amino acid at position 20,
(c) substituting Asn for the amino acid at position 22,
(d) substituting Leu for the amino acid at position 24, and
25 (e) substituting His for the amino acid at position 27.
5. The method of claim 1, wherein said substituting is accomplished by a substitution selected from the group consisting of:
(a) substituting the mature human IFN α sequence between positions 19-27, with a 9-mer
30 defined by SEQ ID NO:2,
(b) substituting the mature human IFN α sequence between positions 11-27, with a 17-mer defined by SEQ ID NO:4, and
(c) substituting the mature human IFN α sequence between positions 6-27, with a 22-mer defined by SEQ ID NO:6.

35

6. The method of claim 1, where the mature human IFN α sequence between positions 28-166 is substantially unchanged.

7. A low-toxicity human IFN α analog for use in human therapy, comprising
5 a mature human IFN α having one or more substituted amino acids prepared by substituting said amino acids according to the method of claim 1.

8. The analog of claim 7, wherein the substituted amino acid is a nonconserved amino acid at one or more of the positions 19, 20, 22, and 27.

10

9. The analog of claim 7, wherein said substituting includes one or more of:

- (a) substituting a class III amino acid for the amino acid at position 19,
- (b) substituting a class IV amino acid for the amino acid at position 20,
- (c) substituting a class III amino acid for the amino acid at position 22,
- 15 (d) substituting a class V amino acid for the amino acid at position 24, and
- (e) substituting a class IV amino acid for the amino acid at position 27.

10. The analog of claim 7, wherein said substituting includes one or more of:
- (a) substituting Asp for the amino acid at position 19,
 - 20 (b) substituting Arg for the amino acid at position 20,
 - (c) substituting Asn for the amino acid at position 22,
 - (d) substituting Leu for the amino acid at position 24, and
 - (e) substituting His for the amino acid at position 27.

25 11. The analog of claim 7, wherein said substituting is accomplished by a substitution selected from the group consisting of:

- (a) substituting the mature human IFN α sequence between positions 19-27, with a 9-mer defined by SEQ ID NO:2,
- (b) substituting the mature human IFN α sequence between positions 11-27, with a 17-
30 mer defined by SEQ ID NO:4, and
- (c) substituting the mature human IFN α sequence between positions 6-27, with a 22-mer defined by SEQ ID NO:6.

12. The analog of claim 7, where the mature human IFN α sequence between positions
35 28-166 is substantially unchanged.

13. A method of inhibiting viral replication, comprising
contacting cells infected with a virus with the low-toxicity human IFN α analog of claim 7
at a concentration effective to inhibit viral replication within said cells.

5

14. A method of inhibiting tumor cell growth, comprising
contacting tumor cells with the low-toxicity human IFN α analog of claim 7 at a
concentration effective to inhibit growth of said tumor cells.

10

15. A method of treating an autoimmune disease in a subject in need of such treatment,
comprising
administering to said subject an effective amount of the low-toxicity human IFN α analog
of claim 7.

15

16. A method of treating chronic inflammation in a subject in need of such treatment,
comprising
administering to said subject an effective amount of the low-toxicity human IFN α analog
of claim 7.

20

17. A method of treating a disease condition responsive to IV administration of IFN α ,
comprising
administering, by oral administration, an effective amount of the low-toxicity human
IFN α analog of claim 7.

1/1

	10	20	27
CDLPETHSLDNRRRTLMLLAQMSRISPS			-- rhIFN- α
CYLSRKLM LD A REN KLLDRMNR LSPH			-- roIFN- τ
<hr/>			
CYLSRKLM LD A REN KLLDRMNR LSPH			-- IFN α -N0
CYLSR THSLDNRRRTLMLLAQMSRISPS			-- IFN α -N1
CYLSRKLM LDNRRRTLMLLAQMSRISPS			-- IFN α -N2
CYLSRKLM LD A RENLMLLAQMSRISPS			-- IFN α -N3
CYLSRKLM LD A REN KLLDRMNR LSPS			-- IFN α -N4
CDLPE KLM LD A REN KLLDRMNR LSPH			-- IFN α -N5
CDLPETHSLD A REN KLLDRMNR LSPH			-- IFN α -N6
CDLPETHSLDNRRRTLMLL DRMNR LSPH			-- IFN α -N7

Fig. 1

SEQUENCE LISTING

<110> Pepgen Corporation
University of Florida

<120> Low Toxicity Human Interferon Alpha
Analog

<130> 5600-0301.41

<140> to be assigned
<141> 1998-10-20

<150> US 08/954,395
<151> 1997-10-20

<150> US 08/631,328
<151> 1996-04-12

<160> 35

<170> FastSEQ for Windows Version 3.0

<210> 1
<211> 9
<212> PRT
<213> Homo sapiens

<400> 1
Ala Gln Met Ser Arg Ile Ser Pro Ser
1 5

<210> 2
<211> 9
<212> PRT
<213> Ovis aries

<400> 2
Asp Arg Met Asn Arg Leu Ser Pro His
1 5

<210> 3
<211> 17
<212> PRT
<213> Homo sapiens

<400> 3
Asn Arg Arg Thr Leu Met Leu Leu Ala Gln Met Ser Arg Ile Ser Pro
1 5 10 15
Ser

<210> 4
<211> 17
<212> PRT
<213> Ovis aries

<400> 4
 Ala Arg Glu Asn Leu Lys Leu Leu Asp Arg Met Asn Arg Leu Ser Pro
 1 5 10 15
 His

<210> 5
 <211> 22
 <212> PRT
 <213> Homo sapiens

<400> 5
 Thr His Ser Leu Asp Asn Arg Arg Thr Leu Met Leu Leu Ala Gln Met
 1 5 10 15
 Ser Arg Ile Ser Pro Ser
 20

<210> 6
 <211> 22
 <212> PRT
 <213> Ovis aries

<400> 6
 Lys Leu Met Leu Asp Ala Arg Glu Asn Leu Lys Leu Leu Asp Arg Met
 1 5 10 15
 Asn Arg Leu Ser Pro His
 20

<210> 7
 <211> 27
 <212> PRT
 <213> Homo sapiens

<400> 7
 Cys Asp Leu Pro Glu Thr His Ser Leu Asp Asn Arg Arg Thr Leu Met
 1 5 10 15
 Leu Leu Ala Gln Met Ser Arg Ile Ser Pro Ser
 20 25

<210> 8
 <211> 27
 <212> PRT
 <213> Ovis aries

<400> 8
 Cys Tyr Leu Ser Arg Lys Leu Met Leu Asp Ala Arg Glu Asn Leu Lys
 1 5 10 15
 Leu Leu Asp Arg Met Asn Arg Leu Ser Pro His
 20 25

<210> 9
 <211> 166
 <212> PRT
 <213> Homo sapiens

<400> 9

```

Cys Asp Leu Pro Glu Thr His Ser Leu Asp Asn Arg Arg Thr Leu Met
 1           5           10           15
Leu Leu Ala Gln Met Ser Arg Ile Ser Pro Ser Ser Cys Leu Met Asp
           20           25           30
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln Phe
 35           40           45
Gln Lys Ala Pro Ala Ile Ser Val Leu His Glu Leu Ile Gln Gln Ile
 50           55           60
Phe Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Asp
 65           70           75           80
Leu Leu Asp Lys Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu
           85           90           95
Glu Ala Cys Val Met Gln Glu Glu Arg Val Gly Glu Thr Pro Leu Met
           100           105           110
Asn Ala Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile Thr
           115           120           125
Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val
           130           135           140
Arg Ala Glu Ile Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln Glu
 145           150           155           160
Arg Leu Arg Arg Lys Glu
           165

```

```

<210> 10
<211> 166
<212> PRT
<213> Artificial Sequence

```

```

<220>
<221> CHAIN
<222> (1)...(166)
<223> mature HuIFN-alpha analog IFNa-N0

```

```

<400> 10
Cys Tyr Leu Ser Arg Lys Leu Met Leu Asp Ala Arg Glu Asn Leu Lys
 1           5           10           15
Leu Leu Asp Arg Met Asn Arg Leu Ser Pro His Ser Cys Leu Met Asp
           20           25           30
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln Phe
 35           40           45
Gln Lys Ala Pro Ala Ile Ser Val Leu His Glu Leu Ile Gln Gln Ile
 50           55           60
Phe Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Asp
 65           70           75           80
Leu Leu Asp Lys Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu
           85           90           95
Glu Ala Cys Val Met Gln Glu Glu Arg Val Gly Glu Thr Pro Leu Met
           100           105           110
Asn Ala Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile Thr
           115           120           125
Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val
           130           135           140
Arg Ala Glu Ile Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln Glu
 145           150           155           160
Arg Leu Arg Arg Lys Glu
           165

```

<210> 11
 <211> 166
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> CHAIN
 <222> (1)...(166)
 <223> mature HuIFN-alpha analog IFNa-N1

<400> 11
 Cys Tyr Leu Ser Arg Thr His Ser Leu Asp Asn Arg Arg Thr Leu Met
 1 5 10 15
 Leu Leu Ala Gln Met Ser Arg Ile Ser Pro Ser Ser Cys Leu Met Asp
 20 25 30
 Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln Phe
 35 40 45
 Gln Lys Ala Pro Ala Ile Ser Val Leu His Glu Leu Ile Gln Gln Ile
 50 55 60
 Phe Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Asp
 65 70 75 80
 Leu Leu Asp Lys Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu
 85 90 95
 Glu Ala Cys Val Met Gln Glu Glu Arg Val Gly Glu Thr Pro Leu Met
 100 105 110
 Asn Ala Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile Thr
 115 120 125
 Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val
 130 135 140
 Arg Ala Glu Ile Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln Glu
 145 150 155 160
 Arg Leu Arg Arg Lys Glu
 165

<210> 12
 <211> 166
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> CHAIN
 <222> (1)...(166)
 <223> mature HuIFN-alpha analog IFNa-N2

<400> 12
 Cys Tyr Leu Ser Arg Lys Leu Met Leu Asp Asn Arg Arg Thr Leu Met
 1 5 10 15
 Leu Leu Ala Gln Met Ser Arg Ile Ser Pro Ser Ser Cys Leu Met Asp
 20 25 30
 Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln Phe
 35 40 45
 Gln Lys Ala Pro Ala Ile Ser Val Leu His Glu Leu Ile Gln Gln Ile
 50 55 60
 Phe Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Asp
 65 70 75 80
 Leu Leu Asp Lys Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu
 85 90 95

Glu Ala Cys Val Met Gln Glu Glu Arg Val Gly Glu Thr Pro Leu Met
 100 105 110
 Asn Ala Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile Thr
 115 120 125
 Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val
 130 135 140
 Arg Ala Glu Ile Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln Glu
 145 150 155 160
 Arg Leu Arg Arg Lys Glu
 165

<210> 13
 <211> 166
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> CHAIN
 <222> (1)...(166)
 <223> mature HuIFN-alpha analog IFNa-N3

<400> 13
 Cys Tyr Leu Ser Arg Lys Leu Met Leu Asp Ala Arg Glu Asn Leu Met
 1 5 10 15
 Leu Leu Ala Gln Met Ser Arg Ile Ser Pro Ser Ser Cys Leu Met Asp
 20 25 30
 Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln Phe
 35 40 45
 Gln Lys Ala Pro Ala Ile Ser Val Leu His Glu Leu Ile Gln Gln Ile
 50 55 60
 Phe Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Asp
 65 70 75 80
 Leu Leu Asp Lys Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu
 85 90 95
 Glu Ala Cys Val Met Gln Glu Glu Arg Val Gly Glu Thr Pro Leu Met
 100 105 110
 Asn Ala Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile Thr
 115 120 125
 Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val
 130 135 140
 Arg Ala Glu Ile Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln Glu
 145 150 155 160
 Arg Leu Arg Arg Lys Glu
 165

<210> 14
 <211> 166
 <212> PRT
 <213> Artificial Sequence

<220>
 <221> CHAIN
 <222> (1)...(166)
 <223> mature HuIFN-alpha analog IFNa-N4

```

<400> 14
Cys Tyr Leu Ser Arg Lys Leu Met Leu Asp Ala Arg Glu Asn Leu Lys
1      5      10      15
Leu Leu Asp Arg Met Ser Arg Ile Ser Pro Ser Ser Cys Leu Met Asp
20     25     30
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln Phe
35     40     45
Gln Lys Ala Pro Ala Ile Ser Val Leu His Glu Leu Ile Gln Gln Ile
50     55     60
Phe Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Asp
65     70     75     80
Leu Leu Asp Lys Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu
85     90     95
Glu Ala Cys Val Met Gln Glu Glu Arg Val Gly Glu Thr Pro Leu Met
100    105    110
Asn Ala Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile Thr
115    120    125
Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val
130    135    140
Arg Ala Glu Ile Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln Glu
145    150    155    160
Arg Leu Arg Arg Lys Glu
165

```

```

<210> 15
<211> 166
<212> PRT
<213> Artificial Sequence

```

```

<220>
<221> CHAIN
<222> {1}...(166)
<223> mature HuIFN-alpha analog IFNa-N5

```

```

<400> 15
Cys Asp Leu Pro Glu Lys Leu Met Leu Asp Ala Arg Glu Asn Leu Lys
1      5      10      15
Leu Leu Asp Arg Met Asn Arg Leu Ser Pro His Ser Cys Leu Met Asp
20     25     30
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln Phe
35     40     45
Gln Lys Ala Pro Ala Ile Ser Val Leu His Glu Leu Ile Gln Gln Ile
50     55     60
Phe Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Asp
65     70     75     80
Leu Leu Asp Lys Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu
85     90     95
Glu Ala Cys Val Met Gln Glu Glu Arg Val Gly Glu Thr Pro Leu Met
100    105    110
Asn Ala Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile Thr
115    120    125
Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val
130    135    140
Arg Ala Glu Ile Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln Glu
145    150    155    160

```

Arg Leu Arg Arg Lys Glu
165

<210> 16
<211> 166
<212> PRT
<213> Artificial Sequence

<220>
<221> CHAIN
<222> (1)...(166)
<223> mature HuIFN-alpha analog IFNa-N6

<400> 16
Cys Asp Leu Pro Glu Thr His Ser Leu Asp Ala Arg Glu Asn Leu Lys
1 5 10 15
Leu Leu Asp Arg Met Asn Arg Leu Ser Pro His Ser Cys Leu Met Asp
20 25 30
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln Phe
35 40 45
Gln Lys Ala Pro Ala Ile Ser Val Leu His Glu Leu Ile Gln Gln Ile
50 55 60
Phe Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Asp
65 70 75 80
Leu Leu Asp Lys Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu
85 90 95
Glu Ala Cys Val Met Gln Glu Glu Arg Val Gly Glu Thr Pro Leu Met
100 105 110
Asn Ala Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile Thr
115 120 125
Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val
130 135 140
Arg Ala Glu Ile Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln Glu
145 150 155 160
Arg Leu Arg Arg Lys Glu
165

<210> 17
<211> 166
<212> PRT
<213> Artificial Sequence

<220>
<221> CHAIN
<222> (1)...(166)
<223> mature HuIFN-alpha analog IFNa-N7

<400> 17
Cys Asp Leu Pro Glu Thr His Ser Leu Asp Asn Arg Arg Thr Leu Met
1 5 10 15
Leu Leu Asp Arg Met Asn Arg Leu Ser Pro His Ser Cys Leu Met Asp
20 25 30
Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe Asp Gly Asn Gln Phe
35 40 45
Gln Lys Ala Pro Ala Ile Ser Val Leu His Glu Leu Ile Gln Gln Ile
50 55 60


```

Phe Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala Ala Trp Asp Glu Asp
65          70          75          80
Leu Leu Asp Lys Phe Cys Thr Glu Leu Tyr Gln Gln Leu Asn Asp Leu
85          90          95
Glu Ala Cys Val Met Gln Glu Glu Arg Val Gly Glu Thr Pro Leu Met
100        105        110
Asn Ala Asp Ser Ile Leu Ala Val Lys Lys Tyr Phe Arg Arg Ile Thr
115        120        125
Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys Ala Trp Glu Val Val
130        135        140
Arg Ala Glu Ile Met Arg Ser Leu Ser Leu Ser Thr Asn Leu Gln Glu
145        150        155        160
Arg Leu Arg Arg Lys Glu
165

```

```

<210> 18
<211> 172
<212> PRT
<213> Ovis aries

```

```

<400> 18
Cys Tyr Leu Ser Arg Lys Leu Met Leu Asp Ala Arg Glu Asn Leu Lys
1      5      10      15
Leu Leu Asp Arg Met Asn Arg Leu Ser Pro His Ser Cys Leu Gln Asp
20     25     30
Arg Lys Asp Phe Gly Leu Pro Gln Glu Met Val Glu Gly Asp Gln Leu
35     40     45
Gln Lys Asp Gln Ala Phe Pro Val Leu Tyr Glu Met Leu Gln Gln Ser
50     55     60
Phe Asn Leu Phe Tyr Thr Glu His Ser Ser Ala Ala Trp Asp Thr Thr
65     70     75     80
Leu Leu Glu Gln Leu Cys Thr Gly Leu Gln Gln Gln Leu Asp His Leu
85     90     95
Asp Thr Cys Arg Gly Gln Val Met Gly Glu Glu Asp Ser Glu Leu Gly
100    105    110
Asn Met Asp Pro Ile Val Thr Val Lys Lys Tyr Phe Gln Gly Ile Tyr
115    120    125
Asp Tyr Leu Gln Glu Lys Gly Tyr Ser Asp Cys Ala Trp Glu Ile Val
130    135    140
Arg Val Glu Met Met Arg Ala Leu Thr Val Ser Thr Thr Leu Gln Lys
145    150    155    160
Arg Leu Thr Lys Met Gly Gly Asp Leu Asn Ser Pro
165    170

```

```

<210> 19
<211> 527
<212> DNA
<213> Artificial Sequence

```

```

<220>
<221> CDS
<222> (18)...(518)
<223> IFNa-N0 synthetic gene

```

<400> 19
ctaggctcga gaagaga tgt tac ttg tct aga aag ttg atg ttg gac gcc 50
Cys Tyr Leu Ser Arg Lys Leu Met Leu Asp Ala
1 5 10

aga gag aac ttg aag ttg ttg gat aga atg aac aga ctt tct cct cac 98
Arg Glu Asn Leu Lys Leu Leu Asp Arg Met Asn Arg Leu Ser Pro His
15 20 25

tct tgt ctt atg gac aga cac gac ttc ggt ttc cca caa gaa gaa ttt 146
Ser Cys Leu Met Asp Arg His Asp Phe Gly Phe Pro Gln Glu Glu Phe
30 35 40

gac ggt aac caa ttc caa aag gct cca gct atc tct gtc ttg cac gag 194
Asp Gly Asn Gln Phe Gln Lys Ala Pro Ala Ile Ser Val Leu His Glu
45 50 55

ttg atc caa caa att ttc aac ctt ttc act acc aag gac tcc tcc gct 242
Leu Ile Gln Gln Ile Phe Asn Leu Phe Thr Thr Lys Asp Ser Ser Ala
60 65 70 75

gct tgg gac gaa gat ttg ctt gac aag ttc tgt act gag ctt tac caa 290
Ala Trp Asp Glu Asp Leu Leu Asp Lys Phe Cys Thr Glu Leu Tyr Gln
80 85 90

caa ttg aac gac ttg gaa gcc tgt gtc atg caa gaa gag aga gtt gga 338
Gln Leu Asn Asp Leu Glu Ala Cys Val Met Gln Glu Glu Arg Val Gly
95 100 105

gag acc cct ttg atg aac gct gat tcc att ttg gct gtc aag aag tac 386
Glu Thr Pro Leu Met Asn Ala Asp Ser Ile Leu Ala Val Lys Lys Tyr
110 115 120

ttc aga aga att acc ttg tac ctt act gag aag aag tac tct cca tgt 434
Phe Arg Arg Ile Thr Leu Tyr Leu Thr Glu Lys Lys Tyr Ser Pro Cys
125 130 135

gct tgg gag gtt gtt aga gct gaa att atg aga tcc ttg tct ttg tct 482
Ala Trp Glu Val Val Arg Ala Glu Ile Met Arg Ser Leu Ser Leu Ser
140 145 150 155

act aac ctt caa gaa aga ttg aga aga aag gag taa gcggccgcg 527
Thr Asn Leu Gln Glu Arg Leu Arg Arg Lys Glu *
160 165

<210> 20

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Linker 1

<400> 20

ctagaaagtt gatggaattc gacg

24

<210> 21
 <211> 25
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Linker 2

<400> 21
 gttaccgtcg aattccatca acttt 25

<210> 22
 <211> 135
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fragment N1, forward strand

<400> 22
 tcgagaagag atgttacctt tctagaacct actccttgga caacagaaga accttgatgt 60
 tgctagatca aatgtccaga atctccctt cctcttgtct tatggacaga cagacttcg 120
 gttccatca agaag 135

<210> 23
 <211> 135
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fragment N1, reverse strand

<400> 23
 aattcttctt gtgggaaacc gaagtcgtgt ctgtccataa gacaagagga aggggagatt 60
 ctggacattt gggctagcaa catcaagggt cttctgttgt ccaaggagtg ggttctagaa 120
 aggtaacatc tcttc 135

<210> 24
 <211> 100
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fragment N2, forward strand

<400> 24
 tcgagaagag atgttacttg tctagaaagt tgatgttgga caacagaaga acccttatgc 60
 tgctagatca aatgtccaga atctctccat cctcttgtct 100

<210> 25
 <211> 116
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fragment N2, reverse strand

<400> 25
 cgaagtcgtg tctgtccata agacaagagg atggagagat tctggacatt tgagctagca 60
 gcataagggt tcttctgtg tccaacatca actttctaga caagtaacat ctcttc 116

<210> 26
 <211> 100
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fragment N3, forward strand

<400> 26
 tcgagaagag atgttacttg tctagaaagt tgatgttggg cgctagagag aacttgatgc 60
 tgctagctca aatgtccaga atttcccctt cttcttgtct 100

<210> 27
 <211> 116
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fragment N3, reverse strand

<400> 27
 cgaagtcgtg tctgtccata agacaagaag aaggggaaat tctggacatt tgagctagca 60
 gcatcaagtt ctctctagcg tccaacatca actttctaga caagtaacat ctcttc 116

<210> 28
 <211> 100
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fragment N4, forward strand

<400> 28
 tcgagaagag atgttacttg tctagaaagt tgatgcttga cgctagagaa aacttgaagc 60
 ttttggacag aatgtccaga atttcccctt cctcttgtct 100

<210> 29
 <211> 116
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Fragment N4, reverse strand

<400> 29
 cgaagtcgtg tctgtccata agacaagagg atggggaaat tctggacatt ctgtccaaaa 60
 gcttcaagtt ttctctagcg tcaagcatca actttctaga caagtaacat ctcttc 116

<210> 30
 <211> 135
 <212> DNA
 <213> Artificial Sequence

<220>

<223> Fragment N5, forward strand

<400> 30

tcgagaagag atgtgacttg ccagaaaagc ttatgttggg cgccagagaa aacttgaaac	60
ttctagacag aatgaacaga ttgtctccac actcttgtct tatggacaga cacgacttcg	120
gtttccacaca agaag	135

<210> 31

<211> 135

<212> DNA

<213> Artificial Sequence

<220>

<223> Fragment N5, reverse strand

<400> 31

aattcttctt gtgggaaacc gaagtcgtgt ctgtccataa gacaagagtg tggagacaat	60
ctgttcattc tgtctagaag ttccaagttt tctctggcgt ccaacataag cttttctggc	120
aagtcacatc tcttc	135

<210> 32

<211> 100

<212> DNA

<213> Artificial Sequence

<220>

<223> Fragment N6, forward strand

<400> 32

tcgagaagag atgtgacttg cctgaaactc acagtctaga cgccagagag aacttgaagc	60
ttttggacag aatgaacaga ttgtctccac actcttgtct	100

<210> 33

<211> 116

<212> DNA

<213> Artificial Sequence

<220>

<223> Fragment N6, reverse strand

<400> 33

cgaagtcgtg tctgtccata agacaagagt gtggagacaa tctgttcatt ctgtccaaaa	60
gcttcaagtt ctctctggcg tctagactgt gagtttcagg caagtcacat ctcttc	116

<210> 34

<211> 100

<212> DNA

<213> Artificial Sequence

<220>

<223> Fragment N7, forward strand

<400> 34

tcgagaagag atgtgacttg ccagagaccc actcccttga caacagaaga actttgatgc	60
ttctagacag aatgaacaga ttgtcccccac actcttgtct	100

<210> 35
<211> 116
<212> DNA
<213> Artificial Sequence

<220>
<223> Fragment N7, reverse strand

<400> 35
cgaagtcgtg tctgtccata agacaagagt gtggggacaa tctgttcatt ctgtctagaa 60
gcatcaaagt tcttctgttg tcaagggagt gggctctctgg caagtcacat ctcttc 116

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/21936

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07K14/56 A61K38/21 C12N15/20 C12N15/62

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 94 10313 A (WOMEN S RESEARCH INST :UNIV FLORIDA (US)) 11 May 1994 see page 30, paragraph 1 *seq ID 5.15* see page 35, paragraph 1; claim 52 ---	1-17
X	EP 0 240 224 A (INTERFERON SCIENCES INC) 7 October 1987 see claim 3 see abstract --- -/--	1-4, 6-10, 12-17

☒ Further documents are listed in the continuation of box C

☒ Patent family members are listed in annex

Special categories of cited documents

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"S" document member of the same patent family

Date of the actual completion of the international search

4 February 1999

Date of mailing of the international search report

18/02/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Cervigni, S

INTERNATIONAL SEARCH REPORT

Int. onal Application No

PCT/US 98/21936

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of the relevant passages	Relevant to claim No
A	S. DI MARCO ET AL.: "Refolding, isolation and characterisation of crystallizable human interferon-alpha 8 expressed in <i>S. cerevisiae</i> " J. BIOTECHNOLOGY, vol. 50, 1996, pages 63-73, XP002092331 see page 64, column 1, paragraph 1 see figure 3 ---	
A	WO 83 02461 A (CETUS CORP) 21 July 1983 see claims 1-11 ---	
A	CHARLIER M ET AL: "CLONING AND EXPRESSION OF CDNA ENCODING OVINE TROPHOBLASTIN: ITS IDENTITY WITH A CLASS-II ALPHA INTERFERON" GENE, vol. 77, 1989, pages 341-348, XP002058353 ---	
A	SUBRAMANIAM P S ET AL: "DIFFERENTIAL RECOGNITION OF THE TYPE I INTERFERON RECEPTOR BY INTERFERONS TAU AND ALPHA IS RESPONSIBLE FOR THEIR DISPARATE CYTOTOXICITIES" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 92, no. 26, 19 December 1995, pages 12270-12274, XP002038445 -----	

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 98/21936

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 13-17 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/21936

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9410313 A	11-05-1994	AU 689450 B	02-04-1998
		AU 5444994 A	24-05-1994
		AU 7316498 A	10-09-1998
		CN 1090510 A	10-08-1994
		EP 0669981 A	06-09-1995
		JP 8505047 T	04-06-1996
		US 5705363 A	06-01-1998
EP 0240224 A	07-10-1987	US 5738845 A	14-04-1998
		DK 161487 A	01-10-1987
WO 8302461 A	21-07-1983	JP 62296892 A	24-12-1987
		AU 1155083 A	28-07-1983
		CA 1210715 A	02-09-1986
		EP 0098876 A	25-01-1984
		US 4569908 A	11-02-1986
		US 4758428 A	19-07-1988